Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Itm Isotope Technologies Munich SE
Headquarters: Garching, Germany
Website: https://www.itm-radiopharma...
Year Founded: 2004
Status: Private
BioCentury | Mar 6, 2025
Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Feb 7, 2025
Product Development
The radiopharma landscape takes shape in neuroendocrine tumors
Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Jun 21, 2024
Management Tracks
ITM names Cavey CEO, plus PureTech, Brainstorm and more
Plus: New chairs for PureTech, Evexta and updates from PharmaEssentia, Brainstorm, Danaher and more
BioCentury | Jun 7, 2024
Finance
Venture Report: Australia’s Brandon Capital raises its largest fund yet
Plus VC rounds for ITM Isotope, Nucleus and Vilya
BioCentury | May 9, 2024
Management Tracks
Meyrick succeeding CMO Harris at radiopharma ITM
Plus: ALX hires Dillon and updates from Obsidian, YS and more
BioCentury | Jan 20, 2024
Finance
Buysiders are all about market-creating catalysts in 2024
BioCentury’s 32nd Buyside View finds MASH, obesity and pain are among the year’s most closely-watched categories
BioCentury | Dec 1, 2023
Product Development
Radiopharmaceuticals’ multi-dimensional next wave
Target, ligand and radioisotope choices fuel the growing field
BioCentury | Jun 7, 2023
Finance
June 7 Quick Takes: Radiopharma play ITM raises €255M
Plus: LNP company Hopewell emerges with $25M seed round and updates from Mozart, GSK, FibroGen and Deerfield
Items per page:
1 - 10 of 16